| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| 5g | |||
| Other Sizes |
| Targets |
β-lactam
Cefmetazole sodium targets bacterial cell wall synthesis. As a cephalosporin antibiotic, it binds to penicillin-binding proteins (PBPs) within the bacterial cell wall. By binding to these proteins, it inhibits peptidoglycan cross-linking, which is essential for cell wall strength and rigidity. This leads to bacterial cell lysis and death. The compound is effective against a variety of Gram-positive and Gram-negative bacteria. Its N-methyl thiotetrazole side chain contributes to its antimicrobial activity. |
|---|---|
| ln Vitro |
Cefmetazole (U-72791A; Zefazone; CS-1170) has antibiotic affinity to S. aureus with a MIC value of 1.0 mg/L. Cefmetazole has affinity for PBP1, PBP2 and PBP3 with IC50 values of ≤0.3, 0.109 and 0.494 mg/L[1]. |
| ln Vivo |
Cefmetazole (U-72791A; Zefazone; CS-1170) (100 mg/kg; i.h.; twice a day, for 7 days; male ICR mice) alters gut bacterial flora[3]. Animal Model: Male ICR mice[3] Dosage: 100 mg/kg Administration: Subcutaneous injection; twice a day, for 7 days Result: Reduced Peyers patch (PP) lymphocyte cell numbers while decreased bacterial numbers in the small intestine. |
| Enzyme Assay |
Cefmetazole sodium antibacterial susceptibility assays involve determining minimum inhibitory concentrations (MIC) against various bacterial strains. Bacteria are cultured in appropriate media and treated with the compound at varying concentrations. Bacterial growth is monitored by optical density measurements or colony counting. MIC values are determined using standard broth microdilution methods. Time-kill assays may be performed to assess bactericidal activity. Penicillin-binding protein binding assays are performed to confirm target engagement. Assays are performed with appropriate positive controls such as other cephalosporins.
|
| Cell Assay |
Cefmetazole sodium cell-based assays are not typically performed as the compound targets bacteria rather than mammalian cells. Antibacterial activity is assessed in bacterial cultures. For selectivity studies, mammalian cell lines may be used to assess cytotoxicity. Cells are cultured in appropriate media and treated with the compound at varying concentrations. Cell viability is assessed by standard assays. The compound's selectivity for bacterial over mammalian targets is evaluated. Experiments are performed with appropriate controls.
|
| Animal Protocol |
Animal Model: Male ICR mice[3]
Dosage: 100 mg/kg Administration: Subcutaneous injection; twice a day, for 7 days Result: decreased numbers of Peyer's patch (PP) lymphocyte cells and fewer small-intestine bacteria. Cefmetazole sodium in vivo studies are conducted in animal models of bacterial infection. Animals are infected with pathogenic bacteria and treated with Cefmetazole sodium via injection. Bacterial burden in tissues (e.g., blood, urine, skin) is quantified by colony counting. Survival rates and clinical signs are monitored. Pharmacokinetic parameters may be determined from plasma samples. Dosing regimens are optimized based on pharmacokinetic data. Studies are conducted in accordance with institutional animal care guidelines. |
| ADME/Pharmacokinetics |
Cefmetazole sodium (MW 493.52 g/mol, C15H16N7NaO5S3) is a semi-synthetic cephalosporin antibiotic. It contains an N-methyl thiotetrazole side chain. The compound is soluble in water. It is stable under recommended storage conditions. Cefmetazole sodium is a broad-spectrum cephalosporin antimicrobial. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution have been characterized in clinical studies. The compound is administered via injection.
|
| Toxicity/Toxicokinetics |
Cefmetazole sodium is generally well-tolerated at therapeutic doses. The compound is a cephalosporin antibiotic with established safety profiles. Oral LD50 in rats is 3204 mg/kg and in mice is 3228 mg/kg. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation is available from clinical use data.
|
| References |
|
| Additional Infomation |
Cefmetazole sodium is an organosodium salt, the sodium salt form of cefmetazole. It is an antibacterial agent. It contains a cefmetazole (1-) group. Cefmetazole sodium is the sodium salt form of cefmetazole, a second-generation semi-synthetic β-lactam cephalosporin antibiotic with antibacterial activity. Cefmetazole binds to penicillin-binding proteins (PBPs), which are peptidases responsible for the cross-linking of peptidoglycan. By preventing the cross-linking of peptidoglycan, cell wall integrity is disrupted, and cell wall synthesis is halted. Cefmetazole is a semi-synthetic cephalosporin antibiotic with broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. It is highly effective against a variety of infections, and no serious side effects have been found to date.
Cefmetazole sodium is a semi-synthetic, second-generation cephalosporin antibiotic with broad spectrum activity. It is a cephamycin antibiotic effective against bacteria causing urinary tract and skin infections. The compound contains an N-methyl thiotetrazole side chain. It was first approved in 1989. Its molecular formula is C15H16N7NaO5S3 with a molecular weight of 493.52 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C15H16N7NAO5S3
|
|---|---|
| Molecular Weight |
493.52
|
| Exact Mass |
493.027
|
| Elemental Analysis |
C, 36.51; H, 3.27; N, 19.87; Na, 4.66; O, 16.21; S, 19.49
|
| CAS # |
56796-39-5
|
| Related CAS # |
Cefmetazole;56796-20-4
|
| PubChem CID |
23666711
|
| Appearance |
Solid powder
|
| Density |
1.75 g/cm3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
31
|
| Complexity |
824
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S1C([H])([H])C(C([H])([H])SC2=NN=NN2C([H])([H])[H])=C(C(=O)[O-])N2C([C@]([C@@]12[H])(N([H])C(C([H])([H])SC([H])([H])C#N)=O)OC([H])([H])[H])=O.[Na+]
|
| InChi Key |
BITQGIOJQWZUPL-PBCQUBLHSA-M
|
| InChi Code |
InChI=1S/C15H17N7O5S3.Na/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/q+1/p-1/t13-,15+/m1./s1
|
| Chemical Name |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, monosodium salt, (6R-cis)-
|
| Synonyms |
CMZ sodium; U72791A; U 72791A; U-72791A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~253.28 mM)
H2O : ~100 mg/mL (~202.63 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0263 mL | 10.1313 mL | 20.2626 mL | |
| 5 mM | 0.4053 mL | 2.0263 mL | 4.0525 mL | |
| 10 mM | 0.2026 mL | 1.0131 mL | 2.0263 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
